[Development of a hybrid bio-artificial liver]

Area of Science:

• Biotechnology and regenerative medicine
• Hepatology and liver disease research
• Cell biology and tissue engineering

Context:

• Fulminant hepatic failure (FHF) presents a critical medical challenge with high mortality rates globally.
• Liver transplantation is the primary treatment for FHF in many regions, but its availability is limited, particularly in Japan.
• Existing medical management strategies for FHF have not significantly reduced mortality, highlighting the need for alternative therapies.

Purpose:

• To explore the development and requirements of bioartificial liver (BAL) support systems as a therapeutic option for FHF.
• To investigate the critical metabolic criteria for BAL functionality, focusing on cell differentiation and mass.
• To examine the role of cell-extracellular matrix interactions in maintaining hepatocyte function within BAL systems.

Summary:

• Bioartificial liver (BAL) support systems are being developed to aid patients with fulminant hepatic failure (FHF) by substituting metabolic functions.
• Effective BALs require highly differentiated hepatocytes and sufficient cell mass, with cell-extracellular matrix interactions crucial for maintaining hepatocyte function via transcription factors like HNF-1 and HNF-4.
• Clinical trials using BALs with porcine hepatocytes or human hepatoblastoma cells have shown promise, indicating future potential for hybrid liver support systems.

Impact:

• BAL technology offers a potential bridge therapy for FHF patients, improving outcomes by supporting liver function during recovery or awaiting transplantation.
• Advancements in cell biology and biotechnology are enabling the creation of more effective BAL systems, potentially reducing mortality associated with FHF.
• The successful implementation of hybrid liver support systems could revolutionize FHF treatment, providing a viable alternative or supplement to liver transplantation.